window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

radiopharmaceuticals

  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Heidelberg Pharma advances dual ATAC pipeline, secures $20M payment and eyes 2027 funding runway

    Lead multiple myeloma candidate enters Cohort 8; second asset dosed [...]

    May 5, 2026
  • Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Orano Med invests $5M to expand US radiopharma capabilities

    Orano Med has expanded its US research and development center [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    ITM secures $262.5M financing from Blue Owl to drive US launch of radiopharmaceutical for neuroendocrine tumors

    Landmark debt deal enables commercial readiness for ITM-11, supports pipeline [...]

    May 5, 2026
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Research & Development
  • Two-minute digital test matches clinical benchmarks for Alzheimer’s trial screening
    Categories: Clinical & Regulatory, Digital & Data, Research & Development, Therapeutic Areas
  • Nucs AI taps Segmed’s 150 million imaging studies to strengthen oncology AI
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top